On Monday, R1 RCM Inc (NASDAQ:RCM), a healthcare revenue cycle management company, received a revised stock rating from Citi. The firm downgraded the company's stock from Buy to Neutral and adjusted the price target to $14.30, down from the previous $16.00.
The downgrade comes in light of the anticipated acquisition of R1 RCM by private equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice. Citi's revised price target aligns with the acquisition bid of $14.30 per share, which is expected to be accepted by R1 RCM's shareholders.
The acquisition bid follows a comprehensive process that also involved a proposal from New Mountain, which had offered $13.25 per share. Citi believes that the current bid from TowerBrook and Clayton, Dubilier & Rice will stand without contention from higher bidders.
Citi has expressed confidence that the acquisition will not face anti-trust hurdles, reinforcing the expectation that the transaction will be finalized by the end of the year, in line with R1 RCM's projections. The deal's closure is anticipated to proceed smoothly, as per the analyst's comments on the matter.
In other recent news, R1 RCM Inc has been the subject of significant developments. The company is set for acquisition by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) in a cash transaction valued at approximately $8.9 billion. The acquisition, approved by R1's independent director committee, will result in R1 becoming a private company.
Simultaneously, R1 RCM reported Q1 revenues of $604 million and an adjusted EBITDA of $152 million, despite a cyberattack and a customer bankruptcy impacting earnings by $9.5 million. The company's outlook for 2024 anticipates revenue between $2.6 billion to $2.64 billion, and adjusted EBITDA between $625 million to $650 million.
In terms of analyst ratings, firms like RBC Capital, TD Cowen, and Citi Research have maintained a positive stance on the company, while KeyBanc Capital Markets downgraded the company due to concerns related to the cyberattack. Jefferies downgraded R1 RCM stock from Buy to Hold following the announcement of the acquisition.
R1 RCM is also undergoing a tech transformation, integrating automation and AI to enhance its platform and improve profit margins. These are the recent developments that have been shaping the trajectory of R1 RCM Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.